Navigation Links
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
Date:5/4/2009

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.

The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product.

Currently the worldwide market for pain treatments is worth about US$26 billion and is forecast to grow to about $31 billion by 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 billion in 2007. The tramadol market in the US and Europe was worth about $1.1 billion in 2008.

Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.

The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere. "Elan's extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol" said Circ Pharma's Chief Technical Officer, Margot Foynes.

About Circ Pharma

Circ Pharma is a specialty pharmaceutical product development company whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma ha
'/>"/>

SOURCE Circ Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
2. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2009 Results
11. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... ELLICOTT CITY, Md. , July 29, 2014 ... has announced a new and updated program for ... October 10 – 12, 2014 in Amelia ... sponsors, CROs, sites and investigators remains unchanged, however, ... more purposeful exchange and networking opportunity among all ...
(Date:7/29/2014)...  Discovery Laboratories, Inc. (Nasdaq: DSCO),  a specialty ... of respiratory critical care, will report its second quarter ... the open of the U.S. financial markets.  ... teleconference and webcast at 9:00 a.m. Eastern Time that ... management will discuss the 2014 second quarter financial ...
(Date:7/29/2014)... July 29, 2014  ImmunoClin Corporation (IMCL) is ... treatment of infectious diseases as well as nutraceuticals. ... prevention of pathologies like cardiovascular disease, Alzheimer,s disease ... ImmunoClin Corporation will complete the strategic relocation of ... , a key center of North American ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3
... , MONTREAL, Dec. 7 /PRNewswire/ - Enerkem Inc. ... been selected by the U.S. Department of Energy (DOE) to ... of its waste-to-biofuels facility to be located in Pontotoc, Mississippi. ... been selected in the larger demonstration scale project category of ...
... 7 ATS Medical, Inc. (Nasdaq: ATSI ), ... services today announced it has received CE Mark approval ... the European Union, indicating it is compliant with relevant ... The Enable valve is the first surgical aortic valve ...
... ... develop systems biology-driven therapeutics to include small molecules, chemotherapy and RNAi candidates and ... ... announced today that it has acquired Hermes Biosciences, Inc. a private biotechnology company ...
Cached Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3
(Date:7/29/2014)... new study from UC San Francisco is the first ... accumulate overtime and accelerate cellular aging, these negative effects ... and sleeping well. , "The study participants who ... shortening than the ones who didn,t maintain healthy lifestyles, ... lead author Eli Puterman, PhD, assistant professor in the ...
(Date:7/28/2014)... the United States have a circulatory problem of the ... and may even require surgery in serious cases. This ... in turn, limb amputation. , At The University of ... scientists tested a non-surgical preventative treatment in a mouse ... increased blood circulation. Their proof-of-concept study appears in ...
(Date:7/28/2014)... a wild relative of the domestic tomato, has been ... labs headed by Professors Neelima Sinha and Julin Maloof ... new genome information may help breeders produce tastier, more ... the journal Nature Genetics , was lead by ... The UC Davis labs carried out work on the ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... Naturforschung will collaborate on the publication of two ... Palaeobiodiversity and Palaeoenvironments and Marine Biodiversity ... through Springer,s abstracting and indexing services and innovative ... both electronic and print versions. Palaeobiodiversity ...
... Current research suggests that a new technique to ... tissue samples. The related report by Balic et ... tissues from colorectal cancer patients using quantitative high-resolution melting ... Journal of Molecular Diagnostics . DNA in ...
... genome eight years ago, enormous progress has been made ... most human genes is still barely understood. An important ... or protein is to compare its sequence with the ... easier to investigate. From the functions of related genes ...
Cached Biology News:Springer and Senckenberg society to collaborate on life sciences and geosciences journals 2New technique for cancer screening 2Relationships in rank and file 2Relationships in rank and file 3Relationships in rank and file 4
... the standard for sample concentration and drying. ... uses a combination of centrifugal force, heat and ... run. , SC210A comes equipped with:, ... chemical compatibility ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
... The Jouan RC Standard Bio for ... applications of molecular biology and biochemistry for ... The RC systems can be expanded with ... wide selection of rotors (eliminating sample loss ...
... The Jouan RC10 series of vacuum concentrators/centrifugal ... protection features allied to rapid and safe ... can be combined with oil-free or high ... and a wide selection of rotors (eliminating ...
Biology Products: